The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.

The FDA approved a new drug called Zepbound, which activates GLP-1 to help with obstructive sleep apnea, while also resulting ...

An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

while Zepbound’s label now includes treatment for moderate to severe obstructive sleep apnea in obese adults. The study’s authors stressed that research is still ongoing to determine whether ...

The GLP-1 drug tirzepatide (Zepbound) was recently approved for obstructive sleep apnea in people who are obese, in combination with a healthy diet and physical activity. GLP-1 agonists are quite ...

The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare ... cover the drug as a treatment for sleep apnea, they said. Zepbound is expected to ...

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...